Gå direkt till huvudinnehållet

Kawasakis sjukdom

Senast uppdaterad: Senast reviderad:
Sakkunnig:
Definition:
Akut, febril självbegränsande vaskulit av okänd orsak som oftast drabbas barn under 5 år.
Förekomst:
I Sverige beräknas incidensen till 2,9 per 100 000 barn under 16 år och 6,2 per 100 000 barn under 5 år, det vill säga sammantaget cirka 50 barn per år
Symtom:
Symtom är feber i minst fem dagar samt fyra av följande fem kliniska fynd.
Kliniska fynd:
Fyra av följande fem fynd måste konstateras för diagnosen: konjuktivit, makulopapulöst utslag, ensidigt förstorade cervikala lymfkörtlar, slemhinneförändringar på läppar och i munhåla, rodnad och ödem i händer och fotsulor. 
Diagnostik:
Labbprover är inte diagnostiska, men ofta ses leukocytos, trombocytos, förhöjd SR och CRP. 
Behandling:
Immunoglobulin ges intravenöst i kombination med acetylsalicylsyra. Detta sker på sjukhus.
  1. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017; 135: e927. pmid:28356445 PubMed  
  2. Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004; 364: 533-44. PubMed  
  3. Freeman AF, Shulman ST. Kawasaki disease: Summary of the American Heart Association guidelines. Am Fam Physician 2006; 74: 1141-8. PubMed  
  4. Saguil A, Fargo M, Grogan S.Diagnosis and management of Kawasaki disease. Am Fam Physician 2015 Mar 15;91(6):365-371.
  5. Roed C, Skinhøj P. Kawasakis syndrom hos voksne. Ugeskr Læger 2009; 171: 430. Ugeskrift for Læger  
  6. Barnreumatologisk Förening: Nationellt PM för Kawasakis sjukdom, 2018. Hämtad 2019-10-10 reuma.barnlakarforeningen.se  
  7. Brogan P, Burns JC, Cornish J, et al. Lifetime cardiovascular management of patients with previous Kawasaki disease. Heart 2019. pmid:31843876 PubMed  
  8. Newburger JW, Burns JC. Kawasaki disease. Vasc Med 1999; 4: 187 - 202. PubMed  
  9. Harnden A,Tulloh R, Burgner D. Kawasaki disease. BMJ. 2014 Sep 17;349:g5336. doi: 10.1136/bmj.g5336 DOI  
  10. Leung DY, Meissner HC. The many faces of Kawasaki syndrome. Hosp Pract 2000; 35: 77 - 81, 85 - 6, 91 - 4.
  11. Hoffmann TU, Pærregaard A. Kawasaki syndrom - en infektionssygdom?. Ugeskr Læger 2002; 164: 5934-6. PubMed  
  12. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020. www.thelancet.com  
  13. Harnden A, Tulloh R, Burgner D. Kawasaki disease. BMJ. 2014 Sep 17;349:g5336. doi: 10.1136/bmj.g5336. DOI  
  14. Stapp J, Marshall GS. Fulfillment of diagnostic criteria in Kawasaki disease. South Med J 2000; 93: 44 - 77. PubMed  
  15. Stockheim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. J Pediatr 2000; 137: 250 - 2. PubMed  
  16. Yellen ES, Gauvreau K, Takahasi M, et. al. Performance of 2004 American Heart Association Recommendations for Treatment of Kawasaki Disease. Pediatrics 2010; 125: 234-41. Pediatrics  
  17. Burns JC. The riddle of Kawasaki disease. N Engl J Med 2007; 356: 659-61. PubMed  
  18. Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet 2019. pmid:30853151 PubMed  
  19. Platt B, Belarski E, Manaloor J, et al. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin. JAMA Netw Open 2020; 3: e1918565. pmid:31899532 PubMed  
  20. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012 Apr 28;379(9826):1613-20. PMID: 22405251. PubMed  
  21. Brogan PA, Bose A, Burgner D et al. Kawasaki disease: an evidence based approach to diagnosis, treatment and proposals for future research. Arch Dis Child 2002; 86: 286 - 90. PubMed  
  22. Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. Pediatrics 2005; 116: 989-95. Pediatrics  
  23. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006; 149: 336-41. PubMed  
  24. Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2012. PMID:22869678. PubMed  
  25. Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.. Lancet 2014; 383: 1731-1738. doi:10.1016
  26. Zhao QM, Chu C, Wu L, et al. Systemic Artery Aneurysms and Kawasaki Disease. Pediatrics 2019. pmid:31732547 PubMed  
  27. Newburger JW, Takahashi M, Burns JC. Kawasaki Disease. J Am Coll Cardiol. 2016 Apr 12;67(14):1738-49. PMID: 27056781. PubMed  
  • Athena Adeli, legitimerad läkare, Karolinska Institutet